- Global pharma firms interested in local startup's new glaucoma treatment
- President’s Technology Awards 2014 - Professor Subbu Venkatraman, Professor Freddy Boey and Adjunct Associate Professor Tina Wong
- Open research positions for applications
- Open Nanomedicine position for application
- PhD Programme in Future Healthcare @ NITHM
- Amaranth Medical obtains Series C funding
- New nanomedicine by NTU and SERI scientists to bring relief to glaucoma patients
- NTU establishes new $60 million research institute in nanomedicine
- NTU launches new centre to develop innovative eye solutions
- SERI and NTU develop new gel to combat glaucoma post-op scars
Global pharma firms interested in local startup's new glaucoma treatmentWe are pleased to share that the local biotech startup Peregrine Ophthalmic founded by NTU Provost Professor Freddy Boey, MSE Chair Professor Subbu Venkatraman and Adjunct Associate Professor Tina Wong have been featured in The Business Times. Please click here for more details.
President’s Technology Awards 2014We would like to extend our warmest congratulations to Professor Subbu Venkatraman, Professor Freddy Boey and Adjunct Associate Professor Tina Wong for receiving the 2014 President's Technology Award. The prestigious award was presented to the team for their innovative application of nanostructures and novel drug delivery approach to combat blindness from glaucoma. Please click here for more details.
- http://www.mse.ntu.edu.sg/) is seeking to recruit research staff to participate in a multi-disciplinary research programme on Ocular and Cardiovascular Drug Delivery. The programme involves interaction of biologists, chemists, medical doctors, biomedical engineers and materials scientists. There is world-wide interaction among collaborators as part of this programme, with the possibility of exchange visits. Several spin-off companies are anticipated to be formed from this research programme, ensuring continued employment opportunities. Please click here for more details.
- here for more details.
Interdisciplinary Graduate School (IGS) Thematic PhD Research Programmes in Future Healthcare at
Nanyang Institute of Technology in Health and Medicine (NITHM) offer Doctor of Philosophy in the following:
Biodegradable scaffold with nano-materials for treating heart disease (Nanomedicine)
- Bioactivity and controlled release studies of proteins in nanocarriers (Nanomedicine)
- Fundamental studies of sustained release from nanocarriers (Nanomedicine)
- Topical delivery of systemic therapeutic agents for use in skin inflammatory disorders (Skin Research)
Please click here for more information on graduate programmes and application requirements for the latest intake.
Amaranth's core technology involves proprietary methods of creating bio-absorbable polymeric stents which offer a number of benefits over the metal stents currently in use. Amaranth’s stents are self-expanding at body temperature, fully biodegradable, biocompatible and possesses the best mechanical attributes of any biodegradable stent currently being tested or approved.
- The Business Times
The new Institute will have Professor Subbu Venkatraman, as its Director. Professor Chad Mirkin, a celebrated nanotechnology expert, from Northwestern University will serve as Chairman of the institute's advisory committee.
The institute's research will focus on four key areas: diabetes, cardiovascular diseases, ophthalmology and skin therapeutics. Nanomedicine is a relatively new discipline that combines nanomaterials-based detection and treatment of diseases. Among the technologies that are included in the field of Nanomedicine are: nanocarrier-based drug and gene delivery; in vivo imaging using nanoparticles; in vitro diagnostics based on nanomaterials; bioactive implants and nanotoxicology. Nanomedicine aims to explore solutions to medical problems using approaches that use nanotechnology. The working hypothesis is that the nanotechnological solutions are superior to micro or macro technologies for these specific problems.
- Nanowerk News
- ST Online
- CNA Online
- Shin Min Daily News (Chinese)
- ST Online
- Today Online
A gel designed by our team and SERI has proven effective in preventing further scarring in the eyes of patients who have undergone glaucoma surgery. It works by incorporating the drug into the gel and releasing the required drug over two days. A clinical trial has been conducted and it shown a 40 per cent drop in the number of injections needed for patients to prevent scarring after surgery.
- The Straits Times (page A4 and B1)
- Straits Times Online
- Channel News Asia
- Channel 5 Video Clip